Raf inhibitor 2是一种有效的raf激酶抑制剂，能够调节细胞增殖和凋亡过程，适用于癌症研究。

LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.

GNE-9815是一种有效的、高度选择性的泛RAF抑制剂，具有出色的口服生物利用度。它对CRAF和BRAF的Ki值分别为0.062 nM和0.19 nM。与MEK抑制剂Cobimetinib结合使用，GNE-9815可以有效调节MAPK途径，适用于KRAS突变癌症的研究。

KG5是一种口服活性双重 PDGFRβ 和 B-Raf 变构抑制剂，具有抗癌和抗血管生成作用，还能抑制 Flt3、KIT 和 c-Raf，适用于多种癌症的治疗研究，特别是在血管生成相关的肿瘤中具有广泛应用前景。

SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.

Encorafenib is a potent and selective B-Raf^V600E inhibitor, with no significant activity observed against a panel of 100 kinases (IC50>900nM).

(E/Z)-Locostatin是一种RKIP抑制剂，能够破坏RKIP与Raf-1激酶的相互作用，抑制细胞增殖和迁移，在研究肝脏衰竭和细胞迁移中展现重要应用。

GDC-0879 is a potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well, displaying no inhibition known to other protein kinases.

L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.

LY3009120（DP-4978）是一种广谱RAF抑制剂，抑制BRAFV600E、BRAFWT和CRAFWT的IC50值分别为5.8 nM、9.1 nM和15 nM。

Tovorafenib (TAK-580, MLN 2480) 是一种可口服的，具有选择性的广谱的 Raf 抑制剂。Tovorafenib (TAK-580, MLN 2480) 通过抵消 TAK-733 触发的 MEK 反馈激活，导致 MAPK 通路的协调抑制。

Norartocarpetin 是一种酪氨酸酶抑制剂，具有较强的抑制活性，IC50 为 0.47 μM。它作为一种抗褐变剂可用于食品体系的研究，对肺癌细胞 (NCI-H460) 也具有显著的抗癌活性，IC50 为 22 μM。

AZ 628 is a pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.

PLX8394是一种高效、选择性的BRaf抑制剂，对BRAFV600E的IC50约为5 nM。

B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM, equipotent against c-Raf (IC50= 25 nM).

Belvarafenib is a pan-RAF inhibitor, with IC50 values of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF^V600E and C-RAF, respectively.

ZM336372 is an inhibitor of c-Raf with IC50 of 70 nM.

RAF709 is an inhibitor of c-Raf and b-Raf with IC50 of 0.5 nM and 1.8 nM, respectively.

LXH254 is an ATP-competitive inhibitor of Raf with anti-proliferative activity. Phase I.

PLX7904 is a Raf inhibitor, inhibits the growth of two melanoma cell lines (A375 and COLO829) and human colorectal cancer cell line COLO205 that expressed BRAFV600E with IC50 values of 0.17 μM, 0.53 μM, and 0.16 μM, respectively.